Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease. Rautakorpi J, Kolehmainen S, Loyttyniemi E, Bjorkesten CA, et al. Dig Dis Sci 2025 Feb 13. doi: 10.1007/s10620-025-08876.

Read + Share

Amedeo Smart

Independent Medical Education

Rautakorpi J, Kolehmainen S, Loyttyniemi E, Bjorkesten CA, et al. Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2025 Feb 13. doi: 10.1007/s10620-025-08876.
PMID: 39946070